66 completed, 28 unknown, 8 recruiting, 5 not yet recruiting. 119 Phase 1, 45 Phase 2.
Follow Liver Cirrhosis: new trials by email Literature Review of Liver Cirrhosis trials Research Report on Liver Cirrhosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Umbilical Cord Mesenchymal Stem Cell Therapy for Biliary Atresia Umbilical Cord-Mesenchymal Stem Cells (UC-MSC), Kasai Portoenterostomy - Biliary Atresia, Kasai Operation | Phase 1 | Recruiting | Dr Cipto Mangunkusumo General Hospital | 40 | 2026-09-01 | 2026-09-09 |
| Phase I/II Trial of Human Umbilical Cord Mesenchymal Stromal Cells for UDCA-Refractory Primary Biliary Cholangitis Standard background therapy, Placebo, hUC-MSC Dose Level 1 - Primary Biliary Cholangitis | Phase 1 / Phase 2 | Not yet recruiting | Beijing 302 Hospital | 68 | 2026-08-31 | 2026-08-31 |
| FAPI PET Imaging - An Exploratory Study [18F]FAPI-74 PET/CT - Thyroid Pathology, Head and Neck Cancer (H&N) | Phase 1 / Phase 2 | Not yet recruiting | Martin Huellner | 770 | 2026-08-01 | 2026-07-15 |
| Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls Hydronidone capsules - Liver Fibrosis | Phase 1 | Completed | Beijing Continent Pharmaceutical Co, Ltd. | 30 | 2026-03-25 | 2026-08-13 |
| Safety Evaluation of MSC-based Therapy for Liver Cihcrosis Treatment Umbilical cord mesenchymal stem cell-derived extracellular vesicles - Liver Cirrhosis | Phase 1 | Not yet recruiting | Vinmec Research Institute of Stem Cell and Gene Technology | 12 | 2026-03-15 | 2026-03-16 |
| QTc Assessment in a Single-Dose Study of Hydronidone Capsules Hydronidone, Placebo - Hepatic Fibrosis | Phase 1 | Completed | Beijing Continent Pharmaceutical Co, Ltd. | 48 | 2025-12-30 | 2026-08-13 |
| The Phase Ⅰd Clinical Trial of Hydronidone Capsules Hydronidone capsules, Placebo capsules - Liver Fibrosis | Phase 1 | Completed | Beijing Continent Pharmaceutical Co, Ltd. | 138 | 2025-12-24 | 2026-09-21 |
| Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease Saroglitazar Magnesium 1 mg - Cholestatic Liver Disease | Phase 1 | Recruiting | Zydus Therapeutics Inc. | 6 | 2025-08-05 | 2026-09-14 |
| The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial Commensal Bacteria Strains - Liver Diseases, Liver Failure | Phase 1 | Recruiting | University of Chicago | 24 | 2025-08-04 | 2025-11-04 |
| Clinical Outcomes of Early Kasai Surgery With Umbilical Cord MSCs in Biliary Atresia Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs), Kasai Portoenterostomy - Biliary Atresia, Kasai Portoenterostomy | Phase 1 | Not yet recruiting | Universitas Diponegoro | 14 | 2025-06-17 | 2025-06-08 |
| CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver - Liver Diseases, Liver Cancer | Phase 1 / Phase 2 | Recruiting | AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC | 90 | 2025-06-01 | 2025-07-08 |
| The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis. AZD2389, PET scan and radioligand - Liver Fibrosis, Hepatic Cirrhosis | Phase 1 | Completed | AstraZeneca | 8 | 2025-05-26 | 2026-07-27 |
| A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine AZD2389, Quinidine - Advanced Chronic Liver Disease, Healthy Participants | Phase 1 | Completed | AstraZeneca | 16 | 2025-05-12 | 2025-07-25 |
| A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants AZD2389, Midazolam, Caffeine - Advanced Chronic Liver Disease, Healthy Participants | Phase 1 | Completed | AstraZeneca | 16 | 2025-05-08 | 2025-07-24 |
| A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury CS0159 - Primary Biliary Cholangitis | Phase 1 | Completed | Cascade Pharmaceuticals, Inc | 24 | 2025-03-13 | 2025-07-11 |
| A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389 AZD2389 - Hepatic Impairment | Phase 1 | Completed | AstraZeneca | 35 | 2025-02-04 | 2025-09-24 |
| A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants Zibotentan - Liver Cirrhosis | Phase 1 | Completed | AstraZeneca | 30 | 2024-12-05 | 2025-12-04 |
| Safety and Feasibility of Human Umbilical Cord Mesenchymal Stem Cell-Derived Secretome in the Treatment of Liver Cirrhosis: a Comprehensive Evaluation of Fibrosis Reduction, Immunomodulation, and Hepatic Regeneration: a Single Center, Randomized, Phase I Clinical Trial Secretome - Liver Cirrhosis | Phase 1 | Not yet recruiting | Baermed | 54 | 2024-12-01 | 2024-10-08 |
| Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC) PVT201, Placebo - Primary Biliary Cholangitis (PBC) | Phase 1 | Completed | Parvus Therapeutics, Inc. | 24 | 2024-10-15 | 2025-11-24 |
| RTX001 Autologous Engineered Macrophages for Liver Cirrhosis RTX001 - End-stage Liver Disease (ESLD), Cirrhosis, Liver | Phase 1 / Phase 2 | Active not recruiting | Resolution Therapeutics Limited | 30 | 2024-10-15 | 2026-10-05 |
Showing 20 of 119. Sign in to see all of them.
Liver Cirrhosis, Biliary (26) · Fibrosis (14) · Non-alcoholic Fatty Liver Disease (10) · Liver Diseases (8) · Fatty Liver (6) · End Stage Liver Disease (5) · Hepatitis C (4) · Ascites (3) · Biliary Atresia (3) · Cholangitis, Sclerosing (3) · Hepatic Encephalopathy (3) · Liver Cirrhosis, Alcoholic (3) · Pulmonary Fibrosis (3) · Alagille Syndrome (2)
Pathologic Processes (119) · Pathological Conditions, Signs and Symptoms (119) · Digestive System Diseases (118) · Liver Diseases (111) · Fibrosis (105) · Bile Duct Diseases (29) · Biliary Tract Diseases (29) · Cholestasis, Intrahepatic (26) · Cholestasis (24) · Hepatic Insufficiency (9) · Fatty Liver (8) · Liver Failure (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Neoplasms (6)
NRL972 (4) · Ursodeoxycholic Acid (4) · ICG 001 (3) · hydronidone (3) · Congresses as Topic (2) · Portoenterostomy, Hepatic (2) · Rivaroxaban (2) · omega-N-Methylarginine (2) · (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid (1) · 3-((((3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl)methyl)amino)pentanedioic acid (1) · Antithrombin III (1) · Baclofen (1) · Budesonide (1) · Bupropion (1) · Caffeine (1)
AstraZeneca (5) · Beijing 302 Hospital (4) · Norgine (4) · Air Force Military Medical University, China (3) · Baermed (3) · Beijing Continent Pharmaceutical Co, Ltd. (3) · Cascade Pharmaceuticals, Inc (3) · Galecto Biotech AB (3) · GlaxoSmithKline (3) · Kiminori Kimura, MD (3) · Vinmec Research Institute of Stem Cell and Gene Technology (3) · Albireo (2) · Bristol-Myers Squibb (2) · National Center for Research Resources (NCRR) (2) · Royan Institute (2)
United States (37) · China (29) · United Kingdom (7) · Japan (6) · Bulgaria (4) · Germany (4) · Indonesia (4) · Italy (4) · Spain (4) · Iran (3) · Switzerland (3) · Vietnam (3) · Netherlands (2) · Puerto Rico (2) · Romania (2)
Daiming Fan (3) · Kiminori Kimura, MD (3) · Zahariy Krastev, MD (3) · Hamid Gourabi, PhD (2) · Aparna Goel, MD (1) · Aparna R Parikh, MD, MS (1) · Avriana Pety Wardani, MD, Sp.BA (1) · Baoyong Yan, doctor (1)
PMID 10102814, PMID 10655252, PMID 17903050, PMID 18068515, PMID 21233083, PMID 21751289, PMID 21810549, PMID 22282526, PMID 23220074, PMID 24074360, PMID 24561556, PMID 24835895, PMID 24876849, PMID 25329189, PMID 26006200, PMID 26972567, PMID 27148676, PMID 27192671, PMID 28249726, PMID 29859173, PMID 30193962, PMID 31038755, PMID 31632000, PMID 31751317, PMID 32274345, PMID 33123384, PMID 34282496, PMID 35119627, PMID 35605429, PMID 35933430, PMID 36076306, PMID 36442892, PMID 36809835, PMID 36914828, PMID 38344178, PMID 38419761, PMID 38677720, PMID 39358661, PMID 39982546, PMID 40050288, PMID 40341605, PMID 40439725, PMID 40721581, PMID 40907882, PMID 42186982, PMID 42823536
2009 (1), 2014 (1), 2016 (1), 2018 (1), M01RR000051 (1), P30DK034989 (1), R01CA263776 (1), R03DK052344 (1), R21TR002024 (1)